Gallo, Silvina
Calle, Roberto A.
Terra, Steven G.
Pong, Annpey
Tarasenko, Lisa
Raji, Annaswamy http://orcid.org/0000-0002-2430-8160
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin
https://doi.org/10.2337/db18-1140-p
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
https://doi.org/10.1186/s12933-019-0856-7
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
https://doi.org/10.1007/s13300-022-01345-6
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
https://doi.org/10.1186/s12933-019-0856-7
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin
https://doi.org/10.2337/db18-1140-p
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
https://doi.org/10.1186/s12933-019-0856-7
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
https://doi.org/10.2337/dc20-2265
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
https://doi.org/10.1007/s13300-017-0354-4
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
https://doi.org/10.1080/03007995.2019.1583450
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Funding for this research was provided by:
Pfizer Inc
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.
Article History
Received: 29 April 2020
First Online: 9 July 2020